Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.

Chemotherapy-treated testicular cancer survivors are at risk for development of the metabolic syndrome, especially in case of decreased androgen levels. Polymorphisms in the gene encoding steroid 5-α-reductase type II (SRD5A2) are involved in altered androgen metabolism.

We investigated whether single-nucleotide polymorphisms (SNPs) rs523349 (V89L) and rs9282858 (A49T) in SRD5A2 are associated with cardiometabolic status in testicular cancer survivors.

In 173 chemotherapy-treated testicular cancer survivors, hormone levels and cardiometabolic status were evaluated cross-sectionally (median 5 years [range 3-20] after chemotherapy) and correlated with SNPs in SRD5A2.

The metabolic syndrome was more prevalent in survivors who were homozygous or heterozygous variant for SRD5A2 rs523349 compared to wild type (33% versus 19%, P = 0. 032). In particular, patients with lower testosterone levels (<15 nmol/l) and a variant genotype showed a high prevalence of the metabolic syndrome (66. 7%). Mean intima-media thickness of the carotid artery and urinary albumin excretion, both markers of vascular damage, were higher in the group of survivors homozygous or heterozygous variant for rs523349 (0. 62 versus 0. 57 mm, P = 0. 026; 5. 6 versus 3. 1 mg/24 h, P = 0. 017, respectively). No association was found between cardiometabolic status and SNP rs9282858 in SRD5A2.

Metabolic syndrome develops more frequently in testicular cancer survivors homozygous or heterozygous variant for SNP rs523349 in SRD5A2. Altered androgen sensitivity appears to be involved in the development of adverse metabolic and vascular changes in testicular cancer survivors and is a target for intervention.

European journal of cancer (Oxford, England : 1990). 2016 Jan 02 [Epub ahead of print]

Hink Boer, Nico-Derk L Westerink, Renske Altena, Janine Nuver, D A Janneke Dijck-Brouwer, Martijn van Faassen, Frank Klont, Ido P Kema, Joop D Lefrandt, Nynke Zwart, H Marike Boezen, Andries J Smit, Coby Meijer, Jourik A Gietema

Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Laboratory Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Laboratory Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Laboratory Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Laboratory Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Vascular Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Epidemiology, University Medical Center Groningen, University of Groningen, The Netherlands. , Vascular Medicine, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. , Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe